Patents Assigned to Academia Sinica
  • Patent number: 10533034
    Abstract: Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 14, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Alice L. Yu, Kun-Hsien Lin, Tai-Na Wu
  • Patent number: 10533179
    Abstract: Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 14, 2020
    Assignees: Academia Sinica, National Taiwan University, Taipei Medical University
    Inventors: Konan Peck, Pan-Chyr Yang, Yi-Chung Chang, Bo-Tsang Huang, Shauh-Der Yeh
  • Patent number: 10532097
    Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 14, 2020
    Assignee: Academia Sinica
    Inventors: Patrick C. H. Hsieh, Pei-Jung Wu, Steve Roffler, Bill Cheng
  • Publication number: 20200010898
    Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 9, 2020
    Applicant: Academia Sinica
    Inventors: Shie-Liang HSIEH, Ya-Lang HUANG, Tsung-Yu TSAI
  • Publication number: 20200000722
    Abstract: Disclosed herein are novel synthetic polypeptides and uses thereof in the preparation of liposomes. According to embodiments of the present disclosure, the synthetic polypeptide comprises a membrane lytic motif, a masking motif, and a linker configured to link the membrane lytic motif and the masking motif. The linker is cleavable by a stimulus, such as, light, protease, or phosphatase. Once being coupled to a liposome, the exposure to the stimulus cleaves the linker that results in the separation of the masking motif from the membrane lytic motif, which in turn exerts membrane lytic activity on the liposome that leads to the collapse of the intact structure of the liposome, and releases the agent encapsulated in the liposome to the target site. Also disclosed herein are methods of diagnosing or treating a disease in a subject by use of the present liposomes.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 2, 2020
    Applicant: Academia Sinica
    Inventors: Hsien-Ming LEE, Hua-De GAO, Jia-Lin HONG, Chih-Yu KUO, Cheng-Bang JIAN
  • Publication number: 20190388535
    Abstract: A baculovirus displaying a porcine epidemic diarrhea virus S protein or S1 domain thereof is provided for preventing porcine epidemic diarrhea virus infection.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 26, 2019
    Applicant: Academia Sinica
    Inventors: Yu-Chan CHAO, Wei-Ting HSU, Hui-Wen CHANG, Chia-Yu CHANG
  • Patent number: 10504713
    Abstract: An ion trap mass spectrometer and methods for obtaining a mass spectrum of ions by scanning an RF frequency applied to the linear ion trap for mass selective ejection of the ions by using two power amplifiers to apply opposite phases of the RF to x and y electrodes.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: December 10, 2019
    Assignee: Academia Sinica
    Inventors: Chung-Hsuan Chen, I-Chung Lu, Ming-Lee Chu
  • Publication number: 20190365852
    Abstract: Disclosed herein are recombinant baculoviruses suitable for introducing an exogenous gene into a pest insect, particularly, disease-transmitting mosquitos. The recombinant baculovirus is characterized in having a promotor that is any of a HzNV-1 viral early expressing gene pag1, a ceropin gene b1, a defensin gene a4, or hp70 gene; and an exogenous gene operably linked thereto the promoter. Also disclosed herein is a method of introducing an exogenous gene into a pest insect. The method includes transducing the pest insect with a recombinant baculovirus without suppressing the production of microRNAs (miRNAs) in the pest insect, wherein the recombinant baculovirus comprises a promoter of pag1, cecropin b1, defensin gene a, or hp70.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 5, 2019
    Applicants: Academia Sinica, Chung Yuan Christian University, National Defense Medical Center
    Inventors: Yu-Chan CHAO, Nenavath Gopal NAIK, Tzong-Yuan WU, Chang-Chi LIN, Szu-Cheng KUO
  • Patent number: 10495644
    Abstract: The disclosure provides for compositions and methods of making and using a foam composition and its utility in clinical applications.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: December 3, 2019
    Assignee: Academia Sinica
    Inventors: Ying-Chih Chang, Jr-Ming Lai, Jen-Chia Wu, Huai-Lu Chen, Hung-Jen Shao
  • Patent number: 10494334
    Abstract: Provided are novel benzenesulfonamide compounds that inhibit calcium/calmodulin-dependent protein kinase II (CaMKII) and pharmaceutical compositions containing the benzenesulfonamide compounds. Also provided are methods of using the benzenesulfonamide compounds to treat diseases or conditions that are associated with CaMKII activity, such as a flavivirus infection.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: December 3, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Wen-Shan Li, Yi-Ling Lin, Wei-Chia Chen, Yogy Simanjuntak
  • Patent number: 10495645
    Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 3, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Sarah K. C. Cheung, Po-Kai Chuang, Tsui-Ling Hsu
  • Publication number: 20190361004
    Abstract: A method of inhibiting an overactive fibroblast growth factor receptor 3 (FGFR3) in a cell by contacting the cell with a composition that contains an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Also disclosed is a method for treating a disorder associated with an overactive FGFR3 with a composition containing an effective amount of Pheophorbide a, Pyropheophorbide a, or an active derivative thereof. Further, a composition for treating a disorder associated with an overactive FGFR3 is described. The composition contains an ethanol extract of Amaranthus viridis.
    Type: Application
    Filed: February 8, 2018
    Publication date: November 28, 2019
    Applicants: ACADEMIA SINICA
    Inventors: Yuan-Tsong Chen, Yi-Ching Lee, Jer-Yuarn Wu, Hsiao-Jung Kao
  • Patent number: 10487120
    Abstract: Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: November 26, 2019
    Assignee: Academia Sinica
    Inventors: Han-Chung Wu, Chung-Tao Tang
  • Patent number: 10472411
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, that comprised a plurality of phage-displayed scFvs characterized with (1) a specific CS combination; (2) a specific distribution of aromatic residues in each CDR; and (3) a specific sequence in each CDR. The present scFv library could be used to efficiently produce different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: November 12, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Hong-Sen Chen, Ing-Chien Chen, Chao-Ping Tung, Shin-Chen Hou, Chung-Ming Yu, Chi-Kai Yang, Yi-Kai Chiu
  • Patent number: 10434132
    Abstract: The present invention is related to a galactolipids-enriched plant extract, prepared by extracting a plant sample selected from a group consisting of: Gynura divaricata subsp. formosana (Asteraceae) (GD), Murdannia bracteata (C. B. Clarke) J. K. Morton ex D. Y. Hong (Commelinaceae) (MB), and Crassocephalum rabens S. Moore (Asteraceae) (CR) with a series of solvents. A pharmaceutical, nutritional, or healthcare composition for protecting or treating acute fulminant hepatitis, for protecting or treating sepsis or related indication thereof, and a composition for skin whitening are also provided herein. These compositions all comprise effective amounts of the galactolipids-enriched plant extracts or purified compounds thereof as bioactive ingredients.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: October 8, 2019
    Assignee: Academia Sinica
    Inventors: Lie-Fen Shyur, Jia-Hua Feng, Maria Karmella Apaya
  • Publication number: 20190298664
    Abstract: This disclosure provides method and kit for myocardial reperfusion and method for attenuating or reducing myocardial reperfusion injury. By administering protein tyrosine phosphatases inhibitor or a protein tyrosine kinases activator, cardiac injury caused by ischemia/reperfusion will be attenuated or reduced.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 3, 2019
    Applicants: Academia Sinica, Buddhist Tzu Chi Medical Foundation
    Inventors: Tzu-Ching Meng, Chiu-Fen Yang, Michael Yu-Chih Chen
  • Publication number: 20190282625
    Abstract: The invention found that first, the feasibility of transfer of tumor resistance and other healthy longevity characters through transplantation of bone marrow mononuclear cells (BMMNC) or hematopoietic stem cells (HSC)/hematopoietic stem and progenitor cells (HSPC) consisting of genetically engineered EKLF gene encoding the hematopoietic transcription factor EKLF. Secondly, the present invention demonstrates expression of EKLF in the long-term hematopoietic stem cells (LT-HSC), and thus EKLF as a target of regulation of hematopoiesis.
    Type: Application
    Filed: September 13, 2017
    Publication date: September 19, 2019
    Applicant: Academia Sinica
    Inventors: Che-Kun James SHEN, Yu-Chiau SHYU, Chun-Hao HUNG
  • Patent number: 10415033
    Abstract: Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized in having a specific CS combination and a specific sequence in each CDR. The present scFv library is useful in efficiently producing different antibodies with binding affinity to different antigens. Accordingly, the present disclosure provides a potential means to generate different antigen-specific antibodies promptly in accordance with the need in experimental researches and/or clinical applications.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: September 17, 2019
    Assignee: Academia Sinica
    Inventors: An-Suei Yang, Jhih-Wei Jian, Hong-Sen Chen, Yi-Kai Chiu, Hung-Pin Peng, Chao-Ping Tung, Chung-Ming Yu, Wei-Ying Kuo, Hung-Ju Hsu
  • Patent number: 10414809
    Abstract: The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 17, 2019
    Assignee: Academia Sinica
    Inventors: Che-Kun James Shen, Yu-Chiau Shyu
  • Publication number: 20190275345
    Abstract: Ironized viral particles such as ironized adeno-associated viral particles, which may carry a photosensitizer such as a KillerRed protein, and uses thereof in light-triggered virotherapy against tumor.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 12, 2019
    Applicants: Academia Sinica, National Taiwan University
    Inventors: Pan-Chyr Yang, S.-Ja Tseng, Zi-Xian Liao